Mumbai-based pharmaceutical giant Lupin has announced a strategic licensing and supply agreement with South Korea’s Huons Co. to introduce Cyclosporine Ophthalmic Nanoemulsion in Mexico. This collaboration aims to bring advanced treatment for dry eye syndrome and corneal ulcers to the Mexican market.
Cyclosporine Ophthalmic Nanoemulsion, a preservative-free formulation, utilizes cutting-edge nanotechnology to enhance tear production and provide rapid relief for patients with keratoconjunctivitis sicca-related ocular inflammatory disease. This innovative treatment has already gained approval in South Korea, Peru, and multiple Middle Eastern countries, highlighting its efficacy and global acceptance.
Dr. Fabrice Egros, President of Corporate Development and Growth Markets at Lupin, emphasized the significance of this partnership. “Introducing cyclosporine ophthalmic nanoemulsion in Mexico allows us to offer a novel solution that significantly benefits patients suffering from dry eye syndrome. This addition enriches our ophthalmology portfolio and aligns with our commitment to enhancing patient quality of life and vision.”
Yohun Aum, Senior Director and Head of Global Business Division at Huons, echoed this sentiment, marking the agreement as a crucial milestone. “Our entry into the Mexican market with this advanced ophthalmic product underscores our dedication to expanding our global footprint and delivering high-quality healthcare solutions.”
Lupin, a key player in the global pharmaceutical landscape, operates in over 100 markets and is renowned for its extensive range of branded and generic medications. The company holds a leading position in therapeutic areas such as cardiology, diabetes, and respiratory treatments, and continues to invest significantly in research and development to drive innovation.
Huons, a subsidiary of Huons Global, has a rich 60-year history in manufacturing and supplying prescription drugs. The company excels in producing complex sterile formulations, including eye drops and injections, and is actively expanding its presence in biopharmaceuticals, medical devices, and nutraceuticals. Huons also exports US FDA-approved anesthetics to the US, demonstrating its commitment to high-quality pharmaceutical solutions.
This partnership between Lupin and Huons is set to enhance eye care in Mexico, providing patients with access to an advanced treatment that promises faster symptom relief and improved quality of life.
